AKI - Acute Kidney Injury, Ovarian Cancer
Conditions
Brief summary
Ovarian cancer is the most lethal malignant tumor of the female reproductive system. Cytoreduction surgery(CRS) combined with chemotherapy is the primary method for treating ovarian cancer, and complete tumor resection is an important means to improve prognosis. It has been demonstrated that the use of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) following CRS can significantly improve the prognosis of some patients with ovarian cancer. However, HIPEC with cisplatin can lead to acute kidney injury (AKI), a serious complication that can seriously affect the patient's short- and long-term prognosis. NCCN guidelines recommend the use of sodium thiosulfate in all patients receiving HIPEC. This study intends to retrospectively collect clinical characteristics of patients to establish a prediction model for kidney injury, with a view to screening those at high risk of kidney injury for use of sodium thiosulfate for nephrotoxicity rescue in cisplatin HIPEC.
Interventions
PROCEDUREHyperthermic intraperitoneal chemotherapy
Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
Sponsors
The First Affiliated Hospital of Bengbu Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients who received HIPEC with cisplatin following cytoreductive surgery. * Patients diagnosed with ovarian cancer pathologically. * FIGO stage III-IV.
Exclusion criteria
* Use of renal protective drugs such as sodium perthiosulfate. * Any grade of chronic or acute renal disease or other serious complications existed before HIPEC. * Patients with single kidney.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Model prediction Probability | Up to 7 days within CRS-HIPEC | Using the constructed clinical prediction model, the patient's baseline characteristics were input, and the model would output the probability of the patient developing AKI. |
| AUC (Area Under Curve) | Up to 7 days within CRS-HIPEC | The AUC value of the model was calculated using the ROC (Receiver Operating Characteristic) Curve. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of AKI. | Up to 7 days within CRS-HIPEC | The AKI would be diagnosed according to KDIGO 2012 criteria. |
Countries
China
Outcome results
None listed